Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2023 · 10-Q
Revenue$666.00K$666.00K±0.0% vs Q1 2022 Net Income-$3.40M-$3.40MN/M vs Q1 2022 EPS Diluted-$0.08-$0.08N/M vs Q1 2022 Operating Income-$5,208,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,748,000N/M Margins · derivedOperating margin-782.0%+907.5 pt vs Q1 2022
Net margin-509.8%+1098.0 pt vs Q1 2022
ended Mar 31, 2023 · filed May 11, 2023 · 41 d after period end